Clinical trial NCT02453646: Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Official title: Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: End Stage Renal Disease
Lead sponsor: Marvao Medical
Sponsor class: INDUSTRY
First posted: 2015-05-25
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: A U.S. multi-centre post approval registry to analyse the CRBSI rate in patients with the NexSite HD Catheter for long term vascular access for hemodialysis.

Detailed description: This is a U.S. multi - centre, prospective, non-randomized post approval registry. Approximately one hundred and twenty patients will be implanted with a NexSite HD catheter at four to eight U.S. sites where hemodialysis catheters are routinely implanted. Each site may enrol a maximum of 50 patients. Enrolled patients will be followed from device placement to device removal or 180 days post device placement. Patients will be enrolled once only.

The primary endpoint is CRBSI rate related to the NexSite HD catheter. Determination of infection will be decided by the investigator and if necessary adjudicated by the CEC (Clinical Events Committee) based on blood culture results, regardless of whether the catheter is removed.

Secondary endpoints for the study are

* Successful placement and continued use of the NexSite HD device designed for use in patients requiring long term hemodialysis.
* Healing of catheter exit site
* Tunnel Infections
* Exit site infections
* Early non-infectious complications associated with CVCs
* Late non-infectious complications associated with Central Venous Catheters

Eligibility criteria: Inclusion Criteria:

1. The patient shall be 18 - 80 years old.
2. The patient requires the placement of a long term tunnelled HD catheter for administration of hemodialysis.
3. The patient has anticipated survival in excess of 90 days from the anticipated date of catheter placement.
4. The patient has the ability to understand the research subject information and sign a written Informed Consent form which must be obtained prior to initiation of the study.
5. The patient receives the catheter via the internal jugular or subclavian vein.
6. All female patients of child bearing potential must complete a negative pregnancy test and will confirm that they are not breastfeeding.

Exclusion Criteria:

1. The patient is participating in another IRB (Institutional Review Board) clinical trial, which modifies standard-of-care treatment and/or involves an investigational device or drug.
2. The patient has a confirmed or suspected infection, bacteraemia or septicaemia.
3. The patient's physiology is NOT suitable for placement of the NexSite device; this will include an examination of the anatomy at the proposed catheter exit site.
4. The patient is known or suspected to have allergies to the materials used in the construction of the device.
5. The patient has previously suffered from coagulation issues or has had vascular surgery at the proposed placement site.
6. The patient has received radiation treatment at the proposed catheter placement site.
7. The patient has severe chronic obstructive lung disease.
8. The patient is pyretic within 72 hours (temperature ≥38o C or 100.4oF) prior to placement and/or has received antimicrobial drugs within two weeks prior to catheterisation.
9. The patient is female of child bearing potential not using adequate contraception. (Adequate contraception is defined as abstinence, intrauterine device \[IUD\], birth control pills, or spermicidal gel with diaphragm or condom)
10. The patient has another indwelling catheter.
11. The patient has non-healing diabetic foot ulcers.
12. The patient did not give informed consent.
13. The patient would be unavailable for follow-up.
14. The patient is a permanent nursing home resident.
15. The proposed access site is not the internal jugular or subclavian vein.
16. The patient is scheduled to undergo an elective surgical procedure (other than a procedure to create a graft or fistula) within the study timeframe.
17. Any other condition that the Investigator believes should exclude the patient from the study.
18. The patient does not have English or Spanish as their first language.

Primary outcomes:
measure: Number of participants with Catheter-Related Blood Stream Infection (CRBSI)(bacteremia/fungemia) as an adverse event.
timeFrame: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Secondary outcomes:
measure: Number of participants with adverse events associated with device placement and use.
timeFrame: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
measure: Number of participants with unhealed catheter exit sites
timeFrame: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
measure: Number of participants with tunnel infection as an adverse event
timeFrame: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
measure: Number of participants with exit site infection as an adverse event
timeFrame: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
measure: Number of participants with Pneumothorax, haemothorax, arrhythmia, air embolism or arterial perforation as an adverse event.
timeFrame: 1 day of device placement
measure: Number of participants with Catheter dislodgement, Catheter tip dislodgement and catheter thrombosis as an adverse event.
timeFrame: Participants will be followed for the duration of catheter use or to 180 days post device placement (whichever occurs first)
Other outcomes:
Locations:
city: Greenville
country: United States
facility: Eastern Nephrology Associates
state: North Carolina
city: New Bern
country: United States
facility: Eastern Nephology Associates
state: North Carolina
city: Raleigh
country: United States
facility: Capital Nephrology Associates
state: North Carolina
city: Orangeburg
country: United States
facility: South Carolina Nephrology and Hypertension Center Inc
state: South Carolina
city: Lubbock
country: United States
facility: Lubbock Vascular Access Centre
state: Texas
city: San Antonio
country: United States
facility: Renal Associates
state: Texas
Study officials:
affiliation: Capital Nephrology Associates
name: Jeffrey G Hoggard, MD
role: PRINCIPAL_INVESTIGATOR
References: